EBS stock forecast, quote, news & analysis
Emergent BioSolutions Inc offers public health products to the government and healthcare providers... Show more
Emergent BioSolutions (EBS) Stock Analysis: Biodefense Momentum Meets Naloxone Pricing Pressure
Key Takeaways
- EBS shares have pulled back roughly 7% over the trailing 30 days, trading near $6.30 and well below the upper half of the trailing 12-month range.
- Medical countermeasures (MCM) remain the company's growth engine, supported by a steady stream of U.S. and international government contract awards.
- A $191.3 million non-cash NARCAN impairment and lowered 2026 guidance reflect intensifying competition and pricing pressure in the naloxone market.
- A restructuring program targeting roughly $40 million in annualized savings aims to realign costs with a more competitive commercial environment.
- Analyst sentiment is mixed-to-neutral, with a consensus "Hold" rating and price targets suggesting potential upside alongside meaningful execution risk.
Current Market Snapshot
Emergent BioSolutions (EBS) has traded in a relatively tight range in recent weeks, with shares hovering near $6.30 after declining about 7% over the trailing 30 days. That move leaves the stock well below its 52-week high and reflects an ongoing tug-of-war between two competing narratives: a strengthening, government-backed biodefense franchise on one side, and a structurally pressured naloxone business on the other.
The stock remains a volatile, small-cap holding with a beta above 2.0, meaning it tends to move more sharply than the broader market. Trading below key longer-term moving averages, EBS currently reflects investor caution about near-term earnings visibility even as the company continues to announce new contract awards and strategic partnerships.
Emergent BioSolutions (EBS) Business Overview and Competitive Position
Emergent BioSolutions is a specialty biopharmaceutical company focused on public health threats and medical countermeasures. Its portfolio spans two broad areas: a biodefense franchise that includes anthrax vaccines and therapeutics (BioThrax, CYFENDUS, Anthrasil, raxibacumab), smallpox and mpox products (ACAM2000, TEMBEXA), botulism antitoxin (BAT), and an Ebola treatment (Ebanga), and a commercial naloxone franchise led by NARCAN Nasal Spray and KLOXXADO for opioid overdose reversal.
The company also operates a contract development and manufacturing (bioservices) segment, leveraging facilities such as its Canton, Maryland site to support partners. Emergent's competitive strength lies in its decades-long relationships with the U.S. government, the Department of Defense, and BARDA, as well as a rare ability to manufacture products against high-consequence biological threats with limited competition.
Recent Developments Driving EBS
Second-quarter 2026 results underscored the divergence at the heart of the EBS story. Total revenue rose 66% year over year to $234.3 million, driven by accelerated medical countermeasure deliveries to U.S. government customers, and adjusted EBITDA climbed to $96.5 million from $33.1 million a year earlier. Management called the quarter's MCM revenue the highest second-quarter figure for the segment since 2020.
However, the company simultaneously recorded a $191.3 million non-cash impairment charge tied to the NARCAN asset group, pushing reported results to a net loss. Management cited a new 4-milligram over-the-counter naloxone approval, the anticipated launch of a 10-milligram prescription product, and more aggressive pricing across the category. While Emergent says NARCAN retains more than 50% of the market, it expects continued price erosion and roughly flat unit demand.
In response, the company lowered full-year 2026 revenue guidance to $645–$675 million from $720–$760 million and reduced adjusted EBITDA guidance to $130–$150 million, while announcing a restructuring expected to deliver about $40 million in annualized savings, including roughly 90 position reductions and facility closures.
Offsetting these headwinds, Emergent has continued to secure government work, including contract modifications for ACAM2000, botulism antitoxin, and CYFENDUS, a Government of Canada standing offer for NARCAN Nasal Spray, and new manufacturing partnerships with SAB Biotherapeutics and Substipharm Biologics. Regulators in Saudi Arabia and Singapore also expanded ACAM2000's mpox indication, supporting the international diversification strategy.
Trending AI Robots
For investors looking to supplement their own analysis with systematic, data-driven strategies, Tickeron's Trending AI Robots page offers a curated view of the platform's trading bots. Tickeron operates hundreds of AI-powered trading bots that trade across thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary considerably in strategy, timeframe, and performance metrics, giving users a range of approaches to explore rather than a single one-size-fits-all signal. Browsing the section can help traders identify which automated strategies are currently gaining traction in the market.
2026 Outlook and What Investors Should Watch
Emergent's 2026 narrative hinges on whether biodefense contract momentum can outpace naloxone erosion. Key factors to monitor include the timing and size of government contract awards, which can be lumpy from quarter to quarter, and the company's progress toward its revised revenue and adjusted EBITDA targets. Investors should also watch how quickly the restructuring savings materialize and whether management executes on its stated priorities of debt reduction and balance-sheet improvement.
On the commercial side, the competitive landscape for naloxone will be critical, including new product launches, pricing dynamics, and Emergent's ability to defend NARCAN market share through line extensions such as carrying cases and multipacks. International MCM expansion, mpox and Ebola pipeline progress, and any additional business development or acquisition activity represent further catalysts. As with any small-cap biopharmaceutical, execution risk, funding cycles, and regulatory developments will remain central to the stock's trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for EBS shows an upward move is likely
EBS's Aroon Indicator triggered a bullish signal on October 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 177 similar instances where the Aroon Indicator showed a similar pattern. In 149 of the 177 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
EBS moved above its 50-day moving average on September 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for EBS crossed bullishly above the 50-day moving average on September 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +1.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where EBS advanced for three days, in 208 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for EBS moved out of overbought territory on September 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EBS as a result. In 79 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EBS turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 39 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EBS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
EBS broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.931) is normal, around the industry mean (11.138). P/E Ratio (-1.824) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.160) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (0.493) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. EBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of biopharmaceutical products
Industry PharmaceuticalsGeneric